The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Taxol: A Novel Investigational Antimicrotubule Agent
Rowinsky, E. K., Cazenave, L. A., & Donehower, R. C. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.15.1247 · Cited by 1,090
Chemotherapy-induced peripheral neuropathy
Quasthoff, S., & Hartung, H. P. (2002) · Journal of Neurology · doi:10.1007/pl00007853 · Cited by 966
Who should measure quality of life, the doctor or the patient?
Slevin, M., Plant, H., Lynch, D., Drinkwater, J., & Gregory, W. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.20 · Cited by 904
Galer, B. S., & Jensen, M. P. (1997) · Neurology · doi:10.1212/wnl.48.2.332 · Cited by 776
Clinical toxicities encountered with paclitaxel (Taxol).
Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Sg, A., & Rc, D. (1993) · PubMed · Cited by 692
Chemotherapy‐induced neuropathy
Windebank, A. J., & Grisold, W. (2008) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2008.00156.x · Cited by 613
Evaluating quality-of-life and health status instruments: development of scientific review criteria
Lohr, K. N., Aaronson, N. K., Alonso, J., Audrey Burnam, M., Patrick, D. L., Perrin, E. B., & Roberts, J. S. (1996) · Clinical Therapeutics · doi:10.1016/s0149-2918(96)80054-3 · Cited by 591
Pharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Microtubule-Based Transport Systems in Neurons: The Roles of Kinesins and Dyneins
Goldstein, L. S. B., & Yang, Z. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.39 · Cited by 550
Seidman, A. D., Fornier, M. N., Esteva, F. J., Tan, L., Kaptain, S., Bach, A., Panageas, K. S., Arroyo, C., Valero, V., Currie, V., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2587 · Cited by 547
Shy, M. E., Frohman, E. M., So, Y. T., Arezzo, J. C., Cornblath, D. R., Giuliani, M. J., Kincaid, J. C., Ochoa, J. L., Parry, G. J., & Weimer, L. H. (2003) · Neurology · doi:10.1212/01.wnl.0000058546.16985.11 · Cited by 514
Total neuropathy score: Validation and reliability study
Cornblath, D. R., Chaudhry, V., Carter, K., Lee, D., Seysedadr, M., Miernicki, M., & Joh, T. (1999) · Neurology · doi:10.1212/wnl.53.8.1660 · Cited by 449
Correlation of patient and caregiver ratings of cancer pain
Grossman, S. A., Sheidler, V. R., Swedeen, K., Mucenski, J., & Piantadosi, S. (1991) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(91)90518-9 · Cited by 434
Cascinu, S., Catalano, V., Cordella, L., Labianca, R., Giordani, P., Baldelli, A. M., Beretta, G. D., Ubiali, E., & Catalano, G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.061 · Cited by 421
Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies
Thompson, S. W., Davis, L. E., Kornfeld, M., Hilgers, R. D., & Standefer, J. C. (1984) · Cancer · doi:10.1002/1097-0142(19841001)54:7<1269::aid-cncr2820540707>3.0.co;2-9 · Cited by 394
Calhoun, E. A., Welshman, E. E., Chang, C.-H., Lurain, J. R., Fishman, D. A., Hunt, T. L., & Cella, D. (2003) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2003.13603.x · Cited by 392
Recommendations for Evaluating the Validity of Quality of Life Claims for Labeling and Promotion
Leidy, N. K., Revicki, D. A., & Genesté, B. (1999) · Value in Health · doi:10.1046/j.1524-4733.1999.02210.x · Cited by 387
Seidman, A. D., Hudis, C. A., Albanell, J., Albanel, J., Tong, W., Tepler, I., Currie, V, Moynahan, M. E., Theodoulou, M., Gollub, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3353 · Cited by 378
Apfel, S. C., Schwartz, S., Adornato, B. T., Freeman, R., Biton, V., Rendell, M., Vinik, A., Giuliani, M., Stevens, J. C., Barbano, R., et al. (2000) · JAMA · doi:10.1001/jama.284.17.2215 · Cited by 368
For the European Regulatory Issues on Quality of Life Assessment Group, Chassany, O., Sagnier, P., Marquis, P., Fullerton, S., & Aaronson, N. (2002) · Drug Information Journal · doi:10.1177/009286150203600127 · Cited by 365
Chaudhry, V., Rowinsky, E. K., Sartorius, S. E., Donehower, R. C., & Cornblath, D. R. (1994) · Annals of Neurology · doi:10.1002/ana.410350310 · Cited by 363
Gregg, R. W., Molepo, J. M., Monpetit, V. J., Mikael, N. Z., Redmond, D., Gadia, M., & Stewart, D. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.5.795 · Cited by 358
National Cancer Institute (2020) · Definitions · doi:10.32388/jzk490 · Cited by 356
(1999) · PubMed · Cited by 337
Hensley, M. L., Schuchter, L., Lindley, C., Meropol, N., Cohen, G., Broder, G., Gradishar, W., Green, D., Langdon, R., Mitchell, R. B., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3333 · Cited by 335
Gamelin, E., Gamelin, L., Bossi, L., & Quasthoff, S. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.35525 · Cited by 321
Oxaliplatin-safety profile: neurotoxicity
GROTHEY, A. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00399-3 · Cited by 319
Taxol produces a predominantly sensory neuropathy
Lipton, R. B., Apfel, S. C., Dutcher, J. P., Rosenberg, R., Kaplan, J., Berger, A., Einzig, A. I., Wiernik, P., & Schaumburg, H. H. (1989) · Neurology · doi:10.1212/wnl.39.3.368 · Cited by 318
Gable, S. L., Reis, H. T., & Downey, G. (2003) · Psychological Science · doi:10.1111/1467-9280.t01-1-01426 · Cited by 307
Epstein, A. M., Hall, J. A., Tognetti, J., Son, L. H., & Conant, L. (1989) · Medical Care · doi:10.1097/00005650-198903001-00008 · Cited by 306
Bécouarn, Y., Ychou, M., Ducreux, M., Borel, C., Bertheault-Cvitkovic, F., Seitz, J. F., Nasca, S., Nguyen, T. D., Paillot, B., Raoul, J. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2739 · Cited by 301
Rosell, R., Gatzemeier, U., Betticher, D. C., Keppler, U., Macha, H. N., Pirker, R., Berthet, P., Breau, J. L., Lianes, P., Nicholson, M., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf332 · Cited by 299
Oxaliplatin-related side effects: Characteristics and management
Cassidy, J., & Misset, J.-L. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)90016-3 · Cited by 298
The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons
Adelsberger, H., Quasthoff, S., Grosskreutz, J., Lepier, A., Eckel, F., & Lersch, C. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00667-1 · Cited by 290
Maindrault-Goebel, F., Louvet, C., André, T., Carola, E., Lotz, J. P., Molitor, J. L., Garcia, M. L., Gilles-Amar, V, Izrael, V, Krulik, M., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00149-5 · Cited by 290
Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy
Apfel, S. C., Kessler, J. A., Adornato, B. T., Litchy, W. J., Sanders, C., Rask, C. A., & The NGF Study Group* (1998) · Neurology · doi:10.1212/wnl.51.3.695 · Cited by 289
Prevention of Cisplatin Neurotoxicity with an ACTH(4–9) Analogue in Patients with Ovarian Cancer
van der Hoop, R. G., Vecht, C. J., van der Burg, M. E. L., Elderson, A., Boogerd, W., Heimans, J. J., Vries, E. P., van Houwelingen, J. C., Jennekens, F. G. I., Gispen, W. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001113220204 · Cited by 287
Cella, D., Peterman, A., Hudgens, S., Webster, K., & Socinski, M. A. (2003) · Cancer · doi:10.1002/cncr.11578 · Cited by 286
Gill, J. S., & Windebank, A. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1130 · Cited by 278
Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer
Burstein, H. J., Manola, J., Younger, J., Parker, L. M., Bunnell, C. A., Scheib, R., Matulonis, U. A., Garber, J. E., Clarke, K. D., Shulman, L. N., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1212 · Cited by 260
Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast Cancer
Perez, E. A., Vogel, C. L., Irwin, D. H., Kirshner, J. J., & Patel, R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.22.4216 · Cited by 250
Stephens, R. J., Hopwood, P., Girling, D. J., & Machin, D. (1997) · Quality of Life Research · doi:10.1023/a:1026458604826 · Cited by 241
Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721
Mollman, J. E., Glover, D. J., Hogan, W. M., & FURMAN, R. E. (1988) · Cancer · doi:10.1002/1097-0142(19880601)61:11<2192::aid-cncr2820611110>3.0.co;2-a · Cited by 219
Nerve growth factor prevents experimental cisplatin neuropathy
Apfel, S. C., Arezzo, J. C., Lipson, L., & Kessler, J. A. (1992) · Annals of Neurology · doi:10.1002/ana.410310114 · Cited by 210
Rowinsky, E. K., Chaudhry, V., Cornblath, D. R., & Donehower, R. C. (1993) · PubMed · Cited by 208
Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy
Postma, T. J., Heimans, J. J., Muller, M. J., Ossenkoppele, G. J., Vermorken, J. B., & Aaronson, N. K. (1998) · Annals of Oncology · doi:10.1023/a:1008344507482 · Cited by 207
Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing
Forsyth, P. A., Balmaceda, C., Peterson, K., Seidman, A. D., Brasher, P., & Deangelis, L. M. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005805907311 · Cited by 199
Cavaletti, G., Tredici, G., Braga, M., & Tazzari, S. (1995) · Experimental Neurology · doi:10.1006/exnr.1995.1008 · Cited by 185
Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy
Riggs, J. E., Apfel, S. C., Litchy, W. J., Kessler, J. A., Sanders, C., Adornato, B. T., & Rask, C. A. (1999) · Neurology · doi:10.1212/wnl.52.7.1517-a · Cited by 182
Screnci, D., McKeage, M. J., Galettis, P., Hambley, T. W., Palmer, B. D., & Baguley, B. C. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1026 · Cited by 180
Falcone, A., Masi, G., Allegrini, G., Danesi, R., Pfanner, E., Brunetti, I. M., Paolo, A. D., Cupini, S., Tacca, M. D., & Conte, P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.075 · Cited by 180
Smyth, J. F., Bowman, A., Perren, T., Wilkinson, P., Prescott, R. J., Quinn, K. J., & Tedeschi, M. (1997) · Annals of Oncology · doi:10.1023/a:1008211226339 · Cited by 178
Toxic neuropathy in patients with pre-existing neuropathy
Chaudhry, V., Chaudhry, M., Crawford, T. O., Simmons-O’Brien, E., & Griffin, J. W. (2003) · Neurology · doi:10.1212/01.wnl.0000043691.53710.53 · Cited by 173
Cavaletti, G., Cavalletti, E., Oggioni, N., Sottani, C., Minoia, C., D’Incalci, M., Zucchetti, M., Marmiroli, P., & Tredici, G. (2000) · PubMed · Cited by 167
Recent advances in drug-induced neuropathies
Peltier, A. C., & Russell, J. W. (2002) · Current Opinion in Neurology · doi:10.1097/00019052-200210000-00015 · Cited by 165
Cavaletti, G., Tredici, G., Marmiroli, P., Petruccioli, M. G., Barajon, I., & Fabbrica, D. (1992) · Acta Neuropathologica · doi:10.1007/bf00227662 · Cited by 164
Taxol Neuropathy: Electrodiagnostic and Sural Nerve Biopsy Findings
Sahenk, Z. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540190110024 · Cited by 163
Cavaletti, G., Cavalletti, E., Oggioni, N., Sottani, C., Minoia, C., D’Incalci, M., Zucchetti, M., Marmiroli, P., & Tredici, G. (2001) · Journal of the Peripheral Nervous System · doi:10.1046/j.1529-8027.2001.01008-5.x · Cited by 157
Maindrault‐Gœbel, F., de Gramont, A., Louvet, C., André, T., Carola, É., Mabro, M., Artru, P., Gilles-Amar, V., Lotz, J., Izrael, V., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00068-5 · Cited by 157
Mechanism-Based Pharmacokinetic Model for Paclitaxel
Henningsson, A., Karlsson, M. O., Viganò, L., Gianni, L., Verweij, J., & Sparreboom, A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.20.4065 · Cited by 156
Zunino, F., Pratesi, G., Micheloni, A., Cavalletti, E., Sala, F., & Tofanetti, O. (1989) · Chemico-Biological Interactions · doi:10.1016/0009-2797(89)90065-3 · Cited by 156
Reduction of paclitaxel-induced peripheral neuropathy with glutamine.
Vahdat, L. T., Papadopoulos, K. P., Lange, D., Leuin, S. C., Kaufman, E. A., Donovan, D., Frederick, D., Bagiella, E., Tiersten, A., NICHOLS, G. L., et al. (2001) · PubMed · Cited by 149
Molecular markers in male breast carcinoma
Rayson, D., Erlichman, C., Suman, V. J., Roche, P. C., Wold, L. E., Ingle, J. N., & Donohue, J. H. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981101)83:9<1917::aid-cncr6>3.0.co;2-1 · Cited by 149
Maindrault‐Gœbel, F., de Gramont, A., Louvet, C., André, T., Carola, É., Gilles-Amar, V., Lotz, J., Tournigand, C., Mabro, M., Molitor, J., et al. (2000) · Annals of Oncology · doi:10.1023/a:1026520812351 · Cited by 131
Peripheral neurotoxicity of taxol in patients previously treated with cisplatin
Cavaletti, G., Bogliun, G., Marzorati, L., Zincone, A., Marzola, M., Colombo, N., & Tredici, G. (1995) · Cancer · doi:10.1002/1097-0142(19950301)75:5<1141::aid-cncr2820750514>3.0.co;2-u · Cited by 119
Hopwood, P., Stephens, R. J., & Machin, D. (1994) · Quality of Life Research · doi:10.1007/bf00451726 · Cited by 118
The taxanes: toxicity and quality of life considerations in advanced ovarian cancer
Guastalla, J. P., & Dieras, V. C. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601496 · Cited by 116
Phase I trial of weekly paclitaxel in advanced lung cancer.
Akerley, W. A., Glantz, M., Choy, H., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.153 · Cited by 110
Calhoun, E. A., Chang, C., Welshman, E. E., Fishman, D. A., Lurain, J. R., & Bennett, C. L. (2001) · The Oncologist · doi:10.1634/theoncologist.6-5-441 · Cited by 109
Cascinu, S., Labianca, R., Alessandroni, P., Marcellini, M., Silva, R. R., Pancera, G., Testa, E., Martignoni, G., Barni, S., Frontini, L., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.11.3313 · Cited by 103
Peripheral neuropathy secondary to docetaxel (Taxotere)
New, P., Jackson, C. E., Rinaldi, D. A., Burris, H. A., & Barohn, R. J. (1996) · Neurology · doi:10.1212/wnl.46.1.108 · Cited by 98
Connelly, E. F., Markman, M. M., KENNEDY, A. W., Webster, K. D., Kulp, B., Peterson, G., & Belinson, J. L. (1996) · Gynecologic Oncology · doi:10.1006/gyno.1996.0210 · Cited by 98
Neurological toxicity of long‐term (>1 yr) thalidomide therapy in patients with multiple myeloma
Tosi, P., Zamagni, E., Cellini, C., Plasmati, R., Cangini, D., Tacchetti, P., Perrone, G., Pastorelli, F., Tura, S., Baccarani, M., et al. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00382.x · Cited by 98
Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice
Verdú, E., Vilches, J., Rodr�guez, F. J., Ceballos, D., Valero‐Cabré, A., & Navarro, X. (1999) · Muscle & Nerve · doi:10.1002/(sici)1097-4598(199903)22:3<329::aid-mus5>3.0.co;2-8 · Cited by 88
Wasserheit, C., Frazein, A., Oratz, R., Sorich, J., Downey, A., Hochster, H. S., Chachoua, A., Wernz, J., Zeleniuch‐Jacquotte, A., Blum, R. H., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.1993 · Cited by 88
Peterson, E. R., & Crain, S. M. (1982) · Science · doi:10.1126/science.6124041 · Cited by 87
Aebi, S. P., Assereto, R., & Lauterburg, B. H. (1991) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1991.tb01366.x · Cited by 84
Neuropeptides and Morphological Changes in Cisplatin-Induced Dorsal Root Ganglion Neuronopathy
Barajon, I., Bersani, M., Quartu, M., et al. (1996) · Experimental Neurology · doi:10.1006/exnr.1996.0050 · Cited by 84
Henningsson, A., Sparreboom, A., Sandström, M., Freijs, A., Larsson, R. L., Bergh, J. C. S., Nygren, P., & Karlsson, M. O. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00126-6 · Cited by 81
Moore, D. H., Donnelly, J. P., McGuire, W. P., Almadrones, L., Cella, D. F., Herzog, T. J., & Waggoner, S. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.086 · Cited by 80
Amelioration of Experimental Cisplatin and Paclitaxel Neuropathy with Glutamate
Boyle, F. M., Wheeler, H., & Shenfield, G. M. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006124917643 · Cited by 79
Neurophysiological Study of Peripheral Neuropathy after High-Dose Paclitaxel
Openshaw, H., Beamon, K., Synold, T. W., Longmate, J., Slatkin, N. E., Doroshow, J. H., Forman, S. J., Margolin, K. A., Morgan, R. J., Shibata, S., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0772-03 · Cited by 78
Paclitaxel (Taxol) induces cumulative mild neurotoxicity
van Gerven, J., Moll, J. W. B., van den Bent, M. J., Bontenbal, M., van der Burg, M. E. L., Verweij, J., & Vecht, C. J. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90459-6 · Cited by 77
Chemotherapy-induced peripheral neuropathy.
Hilkens, P. H. E., & van den Bent, M. J. (1997) · PubMed · Cited by 75
Masurovsky, E. B., Peterson, E. R., Crain, S. M., & Horwitz, S. B. (1983) · Neuroscience · doi:10.1016/0306-4522(83)90148-3 · Cited by 75
Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity.
Dr, G., Perez, E. A., Weibe, et al. (1991) · PubMed · Cited by 75
Konings, P. N. M., Makkink, W. K., Delft, A. M. L. V., & Ruigt, G. F. (1994) · Brain Research · doi:10.1016/0006-8993(94)91873-2 · Cited by 72
Tulub, A. A., & Стефанов, В. Е. (2001) · International Journal of Biological Macromolecules · doi:10.1016/s0141-8130(00)00159-8 · Cited by 71
Glutamate ameliorates experimental vincristine neuropathy.
Boyle, F. M., Wheeler, H., & Shenfield, G. M. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20981-8 · Cited by 69
Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy
Berger, T., Malayer, R., Doppelbauer, A., Krajnik, G., Huber, H. P., Auff, E., & Pirker, R. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00103-2 · Cited by 67
New chemotherapy approaches in colorectal cancer
Grothey, A. A., & Schmoll, H. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200107000-00011 · Cited by 64
Akerley, W., Herndon, J. E., Egorin, M. J., Lyss, A. P., Kindler, H. L., Savarese, D. M. F., Sherman, C. A., Rosen, D. M., Hollis, D. R., Ratain, M. J., et al. (2003) · Cancer · doi:10.1002/cncr.11375 · Cited by 61
Müller, L. J., van der Hoop, R. G., Delft, C. M. M.-V., Gispen, W. H., & Roubos, E. W. (1990) · PubMed · Cited by 59
The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo
Hovestadt, A., van der Burg, M. E. L., Verbiest, H. B. C., van Putten, W. L. J., & Vecht, C. J. (1992) · Journal of Neurology · doi:10.1007/bf00833914 · Cited by 56
Quantitation of Cremophor EL in Human Plasma Samples Using a Colorimetric Dye-Binding Microassay
Sparreboom, A., Loos, W. J., Verweij, J., de Vos, A. I., van der Burg, M. E. L., Stoter, G., & Nooter, K. (1998) · Analytical Biochemistry · doi:10.1006/abio.1997.2467 · Cited by 53
Effect of cisplatin and ACTH4–9 on neural transport in cisplatin induced neurotoxicity
Russell, J. W., Windebank, A. J., McNiven, M. A., Brat, D. J., & Brimijoin, W. S. (1995) · Brain Research · doi:10.1016/0006-8993(95)00100-5 · Cited by 53
Offidani, M., Corvatta, L., Marconi, M., Malerba, L., Mele, A., Olivieri, A., Brunori, M., Catarini, M., Candela, M., Capelli, D., et al. (2004) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00238.x · Cited by 51
Vincristine neurotoxicity in the presence of hereditary neuropathy
Trobaugh‐Lotrario, A. D., Smith, A., & Odom, L. F. (2002) · Medical and Pediatric Oncology · doi:10.1002/mpo.10105 · Cited by 46
Cytoplasmic dynein and microtubule transport in the axon: The action connection
Pfister, K. K. (1999) · Molecular Neurobiology · doi:10.1007/bf02742435 · Cited by 46
Effect of MAP2, MAP2c, and tau on kinesin-dependent microtubule motility
Heins, S., Song, Y., Wille, H., Mandelkow�, E., & Mandelkow, E. (1991) · Journal of Cell Science · doi:10.1242/jcs.1991.supplement_14.24 · Cited by 39
In vitro mechanism study of microtubule assembly inhibition by cis-dichlorodiammine-platinum(II)
Peyrot, V., Briand, C. M., Momburg, R., & Sari, J. C. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90207-8 · Cited by 38
Paclitaxel in Advanced Non-Small Cell Lung Cancer
Akerley, W. (2000) · CHEST Journal · doi:10.1378/chest.117.4_suppl_1.152s · Cited by 37
Hausheer, F. H., Kochat, H., Parker, A. R., Ding, D., Yao, S., Hamilton, S. E., Petluru, P., Leverett, B. D., Bain, S., & Saxe, J. D. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0653-5 · Cited by 33
Self-citationOncosurgery: A new reality in metastatic colorectal carcinoma
Topham, C., & Adam, R. A. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)90015-1 · Cited by 30
Schmoll, H. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)90018-7 · Cited by 29
Action of hydrolyzed cisplatin and some analogs on microtubule protein polymerization in vitro.
Peyrot, V., Briand, C. M., Crevat, A. D., Braguer, D., Chauvet‐Monges, A., & Jc, S. (1983) · PubMed · Cited by 29
Apfel, S. C. (2000) · Cancer Investigation · doi:10.3109/07357900009012196 · Cited by 27
Mayerhofer, K., Bodner‐Adler, B., Bodner, K., Leodolter, S., & Kainz, C. (2000) · PubMed · Cited by 26
Wong, G., Michalak, J. C., Sloan, J. A., Mailliard, J. A., Nikcevich, D. A., Novotny, P. J., Warner, D., Kutteh, L. A., Dakhil, S. R., & Loprinzi, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.8001 · Cited by 22
Treatment and care of neurotoxicity from taxane anticancer agents
Makino, H. (2004) · Breast Cancer · doi:10.1007/bf02968011 · Cited by 21
Peripheral Neuropathy in Cancer Patients
Corbo, M., Balmaceda, C. M., & Balmaceda, C. M. (2001) · Cancer Investigation · doi:10.1081/cnv-100103132 · Cited by 21
Neuroprotection by glutamine synthetase.
Vardimon, L. (2000) · PubMed · Cited by 20
Hollenbeck, P. J. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.152.5.f25 · Cited by 14
Quantitative measurement of vibratory perception threshold using a new vibrometer TM-31A.
KAMON, N. (1994) · PubMed · Cited by 9
Mitchell, P., Goldstein, D. S., Michael, M., Beale, P. J., Friedlander, M. L., Zalcberg, J. R., Clarke, S. J., & White, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3581 · Cited by 7
Cited by
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy
Zajączkowska, R., Kocot-Kępska, M., Leppert, W., Wrzosek, A., Mika, J., & Wordliczek, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061451 · Cited by 829
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21204 · Cited by 741
American Cancer Society Colorectal Cancer Survivorship Care Guidelines
El‐Shami, K., Oeffinger, K. C., Erb, N. L., Willis, A., Bretsch, J. K., Pratt‐Chapman, M. L., Cannady, R. S., Wong, S. L., Rose, J., Barbour, A. L., et al. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21286 · Cited by 475
Mols, F., Beijers, T., Lemmens, V., van den Hurk, C. J., Vreugdenhil, G., & van de Poll-Franse, L. V. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1514 · Cited by 359
Chemotherapy-induced peripheral neurotoxicity
Cavaletti, G., & Marmiroli, P. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.160 · Cited by 351
Metadata
- Authors
- Hausheer, F. H., Schilsky, R. L., Bain, S., Berghorn, E. J., & Lieberman, F.
- Venue
- Seminars in Oncology
- Publisher
- Elsevier BV
- Published
- 2006-02
- Volume
- 33
- Issue
- 1
- Pages
- 15-49
- ISSN
- 0093-7754 (ISSN-L)
- OpenAlex
- W2141505882
- Cited by
- 408
- References
- 121
- FWCI
- 6.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.